Next Article in Journal
Systematic Meta-Analysis Identifies Co-Expressed Kinases and GPCRs in Ovarian Cancer Tissues Revealing a Potential for Targeted Kinase Inhibitor Delivery
Previous Article in Journal
Understanding and Kinetic Modeling of Complex Degradation Pathways in the Solid Dosage Form: The Case of Saxagliptin
Open AccessArticle

Effectiveness of a Pharmacogenetic Tool at Improving Treatment Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Clinical Studies

1
AB-Biotics, S.A., Av. de la Torre Blanca 57, 08172 Sant Cugat del Valles, Barcelona, Catalonia, Spain
2
Department of Psychiatry and Psychology, Institute of Neuroscience, C/ Villaroel, 170, 08036 Barcelona, Catalonia, Spain
3
Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, C/ Rosselló, 149, 08036 Barcelona, Catalonia, Spain
4
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain
5
Servei de Psiquiatria, Hospital de la Santa Creu i Sant Pau, C/ Sant Antoni Maria Claret, 167, 08025 Barcelona, Catalonia, Spain
6
Institut d’Investigacions Biomèdica Sant Pau, Universitat Autònoma de Barcelona, 08025 Barcelona, Catalonia, Spain
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2019, 11(9), 453; https://doi.org/10.3390/pharmaceutics11090453
Received: 9 July 2019 / Revised: 28 August 2019 / Accepted: 29 August 2019 / Published: 2 September 2019
(This article belongs to the Special Issue Pharmacogenomics in Psychiatry)
Several pharmacogenetic tests to support drug selection in psychiatric patients have recently become available. The current meta-analysis aimed to assess the clinical utility of a commercial pharmacogenetic-based tool for psychiatry (Neuropharmagen®) in the treatment management of depressive patients. Random-effects meta-analysis of clinical studies that had examined the effect of this tool on the improvement of depressive patients was performed. Effects were summarized as standardized differences between treatment groups. A total of 450 eligible subjects from three clinical studies were examined. The random effects model estimated a statistically significant effect size for the pharmacogenetic-guided prescription (d = 0.34, 95% CI = 0.11–0.56, p-value = 0.004), which corresponded to approximately a 1.8-fold increase in the odds of clinical response for pharmacogenetic-guided vs. unguided drug selection. After exclusion of patients with mild depression, the pooled estimated effect size increased to 0.42 (95% CI = 0.19–0.65, p-value = 0.004, n = 287), corresponding to an OR = 2.14 (95% CI = 1.40–3.27). These results support the clinical utility of this pharmacogenetic-based tool in the improvement of health outcomes in patients with depression, especially those with moderate–severe depression. Additional pragmatic RCTs are warranted to consolidate these findings in other patient populations. View Full-Text
Keywords: antidepressants; depression; genetic; pharmacogenetics; psychiatry; randomized controlled trials antidepressants; depression; genetic; pharmacogenetics; psychiatry; randomized controlled trials
Show Figures

Figure 1

MDPI and ACS Style

Vilches, S.; Tuson, M.; Vieta, E.; Álvarez, E.; Espadaler, J. Effectiveness of a Pharmacogenetic Tool at Improving Treatment Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Clinical Studies. Pharmaceutics 2019, 11, 453.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop